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ABSTRACT
Ralstonia pickettii can be isolated from water, soil and plants, and can also form part of the commensal
ﬂora of the oral cavity and the upper respiratory tract of healthy individuals. R. pickettii is an infrequent
pathogen, but can cause infections, mainly of the respiratory tract, in immunocompromised and cystic
ﬁbrosis patients. It can be isolated from a variety of clinical specimens, including sputum, blood, wound
infections, urine, ear and nose swabs, and cerebrospinal ﬂuid. Resistance can occur to ciproﬂoxacin,
trimethoprim–sulphamethoxazole, piperacillin–tazobactam, imipenem–cilastatin and ceftazidime. Early
detection of R. pickettii allows prompt appropriate antimicrobial therapy with a favourable outcome, but
removal of infected indwelling devices is mandatory.
Keywords Antimicrobial susceptibility, cystic ﬁbrosis patients, immunocompromised patients, infections, Ralsto-
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The human body exists within a ubiquitous
microbiological environment in a delicate symbi-
otic equilibrium that protects against overwhelm-
ing growth of the commensal bacterial ﬂora.
When this balance is disturbed, some commensal
organisms of relatively low virulence, such as
Ralstonia pickettii, formerly named Pseudomonas
(Burkholderia) pickettii, can cause severe disease.
First described in 1973, R. pickettii is characterised
as a Gram-negative aerobic bacillus that is phe-
notypically homogeneous with other known
pseudomonads [1,2]. To date, 11 species of
Ralstonia have been described, namely R. pickettii,
R. solanacearum, R. eutropha, R. gilardii, R. paucula,
R. basilensis, R. oxalatica, R. mannitolitytica, R.
taiwanensis, R. campinensis and R. metaliidurans
[2]. R. pickettii can be isolated from water, soil
and plants, and can form part of the commensal
ﬂora of the oral cavity and upper respiratory tract
[2,3]. In healthy individuals, infections with
Ralstonia spp. are extremely rare. However, in
individuals with declining immunocompetence,
R. pickettii may progress to become a pathogen
that causes infections, mainly of the respiratory
tract. R. pickettii is also able to invade the
bloodstream [2].
Aside from acquired or therapeutic immuno-
suppression, cystic ﬁbrosis (CF) is the single most
important known risk-factor for acquiring an
infection with R. pickettii [1–3]. In CF patients,
R. pickettii may be responsible for chronic airway
infections and pneumonia [2]. Nosocomial out-
breaks of infections with R. pickettii have been
reported in association with contaminated ﬂuids
used for patient care [1,3–6]. R. pickettii bacterae-
mia has been reported in association with central
venous line or permanent intravenous system
infection, secondary to the use of such ﬂuids [7,8].
In many cases, patients with systemic R. pickettii
infections are immunocompromised.
Between 2001 and 2004, 38 patients with clin-
ically manifest R. pickettii infections were identi-
ﬁed at Innsbruck Medical University, Austria (a
tertiary referral centre). Twenty-three patients
yielded an R. pickettii isolate from a single
specimen, seven patients yielded R. pickettii iso-
lates from two specimens, and six patients
yielded R. pickettii isolates from three or more
specimens (Table 1). In this series, 34% of the
cases involved infections of the respiratory tract
in patients with CF, mostly as part of mixed
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infections. As with other pathogens, colonisation
of the respiratory tract of CF patients with R.
pickettii may be asymptomatic, and therefore a
decision of when to start antimicrobial treatment
is difﬁcult [2–4]. In non-CF patients, R. pickettii
respiratory tract infection was a rare event, with
only two cases (a patient with chronic obstructive
pulmonary disease and a poly-traumatised
patient receiving ventilator support). While res-
piratory tract and other non-systemic infections
responded well to systemic antibiotic treatment,
intravenous antibiotic therapy showed no success
in cases of R. pickettii sepsis if a contaminated
central venous line or permanent venous system
was the source. Blood cultures accounted for 43%
and contaminated ‘port-a-cath’ systems for 8% of
the R. pickettii isolates in this series. This type of
infection remains a signiﬁcant complication, as
such systems are implanted commonly in critic-
ally-ill or cancer patients [8]. In all three patients
with infected ‘port-a-cath’ systems, and another
three patients with contaminated central venous
lines, removal of the indwelling device was
necessary to control infection. The spectrum of
pathogens associated with line sepsis or contam-
inated implantable devices is expanding, and
non-fermentative bacilli must be considered as
important potential pathogens. Compared with
sepsis and respiratory tract infection, all other
infections with R. pickettii, such as urinary tract
infections, wound infections, and infections of the
ear and nose, were rare (Table 1). To date, such
infections have been reported only anecdotally, or
not at all. These rare infections all responded to
antibiotic treatment.
Isolation and identiﬁcation of R. pickettii can
be performed according to standard microbiolo-
gical methods on MacConkey agar. R. pickettii
strains are glucose-non-fermentative Gram-
negative bacilli, and can be identiﬁed readily
with commercial identiﬁcation systems (e.g.,
API 20NE; bioMe´rieux, Marcy l’Etoile, France).
Alternatively, PCR-based methods may produce
more accurate results. Thus, Coenye et al. [2]
used two combined PCR assays to identify
Ralstonia spp. in the sputum of CF patients,
and concluded that the frequency of these
bacteria in this patient population may be
underestimated. Routine PCR-based identiﬁca-
tion of non-fermentative bacilli cannot, to date,
be provided by most laboratories, but might be
useful for monitoring outbreaks.
Antimicrobial susceptibility testing can be per-
formed with NCCLS disk-diffusion methods on
Mueller–Hinton agar. Determination of MICs may
be of use in refractory cases. The Ralstonia group
has been reported to be susceptible to co-trim-
oxazole, ciproﬂoxacin and anti-pseudomonal
b-lactams, with aminoglycosides having activity
against some isolates [3,9]. In the series described
above, the R. pickettii isolates showed resistance
to ciproﬂoxacin (17%), trimethoprim–sulphameth-
oxazole (26%), aztreonam (60%), piperacillin–
tazobactam (45%), ceftriaxone (40%), ceftazidime
(30%), imipenem–cilastatin (38%) and amino-
glycosides (> 60%). However, the possibility of
discrepancies between in-vitro testing and in-vivo
activity should always be considered [1–4,8–10].
Thus, while being low in total numbers, infec-
tions with R. pickettii may affect immunocompro-
mised patients or patients suffering from CF
[2,11,12]. Contaminated medical solutions are
one of the most important sources of R. pickettii
[4,5,13–15]. PCR-based identiﬁcation and other
new systems may be able to improve the efﬁ-
ciency of diagnosis [16–18]. R. pickettii produces a
wide range of b-lactamases. OXA-60, a chromo-
somal, inducible, imipenem-hydrolysing class D
b-lactamase, has recently been described in detail
[19]. As emphasised previously, delayed diagno-
sis and misinterpretation can be hazardous to
patients with infections caused by R. pickettii [20].
Early detection of R. pickettii allows prompt
directed antibacterial treatment, according to the
results of susceptibility tests, and is associated
with a favourable outcome, but removal of infec-
ted indwelling devices is mandatory [18].
Table 1. Demographic and clinical data from patients
with Ralstonia pickettii infection at Innsbruck Medical
University, Austria
Patients, n 38
Median age, years (range) 35.9 (1.4–81.0)
Gender, male:female 22 : 16
Clinical samples yielding R. pickettii, n 61a
Sputum, n 24
Blood cultures, n 26
Port-a-cath system, n 5
Miscellaneous specimens, n 6
Predisposing factors
Cystic ﬁbrosis, n 13
Chronic obstructive pulmonary disease, n 2
Malignant disorders, n 7
AIDS, n 1
Acute renal failure, n 1
Diabetes mellitus, renal failure, n 1
Poly-trauma, n 4
Surgery, n 4
aSeventeen mixed infections.
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